Inhibikase Therapeutics, Inc. Annual Operating Margin in % from 2020 to 2023

Taxonomy & unit
ratio: %
Description
The operating margin measures the profit a company makes on a dollar of sales after accounting for the direct costs involved in earning those revenues.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Operating Margin history and growth rate from 2020 to 2023.
  • Inhibikase Therapeutics, Inc. Operating Margin for the quarter ending September 30, 2024 was -2.01B %, a 32475675% decline year-over-year.
  • Inhibikase Therapeutics, Inc. annual Operating Margin for 2023 was -7.71K %, a 47.5% increase from 2022.
  • Inhibikase Therapeutics, Inc. annual Operating Margin for 2022 was -14.7K %, a 2984% decline from 2021.
  • Inhibikase Therapeutics, Inc. annual Operating Margin for 2021 was -476 %, a 18% decline from 2020.
Operating Margin, Annual (%)
Operating Margin, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date
2023 -7.71K +6.97K +47.5% Jan 1, 2023 Dec 31, 2023
2022 -14.7K -14.2K -2984% Jan 1, 2022 Dec 31, 2022
2021 -476 -72.7 -18% Jan 1, 2021 Dec 31, 2021
2020 -404 Jan 1, 2020 Dec 31, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.